This article is more than 5 years old. Information may no longer be current.

RoundTable completes sale of Aqua Pharmaceuticals to Almirall

RoundTable Healthcare Partners has announced the completion of the sale of Aqua Pharmaceuticals Holdings to Almirall S.A.

The deal for up to $402.6 million in cash includes $327.6 million at closing plus $75 million for contingent payments, according to a press release. Almirall, based in Barcelona, Spain, is a global pharmaceutical company focused on treatment including dermatological diseases. Lake Forest, Ill.-based RoundTable held majority interest in Aqua, a West Chester, Pa.-based specialty pharmaceutical company focused on prescription dermatology products.

“The Aqua management team … has created an industry-leading specialty dermatology pharmaceutical company, achieving exceptional growth through its strong sales organization and strategic product acquisitions while making significant R&D investments,” Jack L. McGinley, founding partner of RoundTable and chairman of Aqua, said in the release. “We believe that Almirall will be a strong strategic partner for Aqua.”